Cite
Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations.
MLA
Frézard, Frédéric, et al. “Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations.” Pharmaceutics, vol. 15, no. 1, Jan. 2023, p. 99. EBSCOhost, https://doi.org/10.3390/pharmaceutics15010099.
APA
Frézard, F., Aguiar, M. M. G., Ferreira, L. A. M., Ramos, G. S., Santos, T. T., Borges, G. S. M., Vallejos, V. M. R., & De Morais, H. L. O. (2023). Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations. Pharmaceutics, 15(1), 99. https://doi.org/10.3390/pharmaceutics15010099
Chicago
Frézard, Frédéric, Marta M. G. Aguiar, Lucas A. M. Ferreira, Guilherme S. Ramos, Thais T. Santos, Gabriel S. M. Borges, Virgínia M. R. Vallejos, and Helane L. O. De Morais. 2023. “Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations.” Pharmaceutics 15 (1): 99. doi:10.3390/pharmaceutics15010099.